Compare TG Therapeutics Inc (TGTX) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? TG Therapeutics Inc trades at $49.59 (market cap $7.64B), while Vanguard Total World Stock Index Fund ETF trades at $161.58. The key difference: Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | VT | |
|---|---|---|
Market Cap | $7.64B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $59.06 | $161.30 |
52-Week Low | $26.94 | $132.19 |
Enterprise Value | $7.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Vanguard Total World Stock ETF (VT) trades at $161.53, up 0.35% on the day, with a bullish technical signal from moving averages. The ETF offers diversified global equity exposure across more than 10,000 stocks, with a low expense ratio of 0.06% (Vanguard, 2026). Recent news highlights institutional activity, including Barry Investment Advisors reducing its stake by 18.7% in Q2 2026 (Defense World, 2026-08-10).
VT provides broad market access but faces risks from trade policy uncertainty and potential market volatility. The neutral oscillator signal and overbought RSI levels suggest near-term consolidation. Long-term appeal lies in cost-efficient global diversification, though investors should weigh geopolitical risks against the fund's historical resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
